Clinical Trial Update: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for KD6001 in combination with anti-PD-1 antibody with or without bevacizumab in advanced hepatocellular carcinoma and other solid tumors …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Other Solid Tumors

Drugs mentioned

• Anti-PD-1 antibody
• Bevacizumab (bevacizumab)
• KD6001

Snippet

Sponsor: Shanghai Kanda Biotechnology Co., Ltd. | Conditions: Advanced HCC, Other Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN